Skip to main content

Pediatric Rheum

SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
Dr. Pascual shows that signatures show IFN or plasmablast or PMN/Myeloid signatures, thus identifying 7 subsets of lupus kids #UTSWSLE2022 https://t.co/3BAxPdAKw8
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Insurance delays in starting TNF Inhibitors in kids w/ Juvenile Idiopathic Arthritis (91% on DMARDs) - prior authorization required in 98%; 26% of PA requests denied & required appeals, w/ 22% delays > 2+ wks, 25% took 30+ days to start TNFi https://t.co/1TGmM8qOHR https://t.co/EpbrNSbNBl
Dr. John Cush @RheumNow( View Tweet )
May 05, 2022
Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z
Dr. John Cush @RheumNow( View Tweet )
May 01, 2022
JIA.oligoarticular.jpg

Biologics for JIA? Not So Fast, Say Insurers

MedPage Today
Apr 25, 2022

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.



Among 54 patients seen at Boston Children's Hospital for newly diagnosed JIA in 2018-2019,

Read Article
FDA approved 1st drug for kids with COVID-19. Veklury (remdesivir) get an expanded indication in Peds >28days old & wt > 3 kg who has SARS-CoV-2 & are Hospitalized, or Not hospitalized & at high risk for severe COVID-19 or death https://t.co/7Hn4CwKjxv

Dr. John Cush @RheumNow( View Tweet )

Apr 25, 2022
Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2

Dr. John Cush @RheumNow( View Tweet )

Apr 19, 2022
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today
Apr 14, 2022

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
Your Hot Topic Questions from RNL 2022 Rheumatologists questions for Dr. Jack Cush QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/wpPeIwiCxe https://t.co/UY3gDaVeTv
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
Retrospective cohort hospital study of 228 children with MIS-C; 215 patients (median age 8 yrs, 63% boys) shows that orticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease https://t.co/HLSR5zOseU https://t.co/5z7I9SVcxI
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
Dr. Jonathan Hausman on JIA Most subjects equivalent to adult forms of inflammatory arthritis - note early onset seronegative oligoarthritis Tips on transitioning to adult care - determine extent of active disease vs. chronic damage @RheumNow #RNL2022 https://t.co/MhjH04PQ3e
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
ILAR classifications vs the reality of disease changes seen in pedi clinics is an issue for continuing care. Dr. @hausmannMD reviews arthritis clusters which may make it easier to understand from an adult rheum perspective. #RNL2022 @RheumNow https://t.co/7xYD96R5Rw
Dr. Rachel Tate @uptoTate( View Tweet )
Mar 20, 2022
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article
ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundationhttps://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy
Dr. John Cush @RheumNow( View Tweet )
Mar 13, 2022
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Mar 11, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Kawasaki.jpg

Kawasaki Disease Guideline from ACR and Vasculitis Foundation

ACR
Mar 09, 2022

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of

Read Article
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis The ACR has updated its clinical guidelines for the management of JIA, with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA.https://t.co/eKv8qubl1v https://t.co/xLBMccCYex
Dr. John Cush @RheumNow( View Tweet )
Mar 07, 2022
Pills.JIA_.png

ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis

Mar 03, 2022

The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported

Read Article
Retrospective study of juvenile dermatomyositis shows 1st line Rx w/ MTX is not effective, esp in MSA Ab+ pts. 45 JDM pts (2/3 severe) Rx w/ 6 mos MTX + steroids; inactive dz seen in 31%, with 42% muscle and 33% skin responses. MSA neg pts did better https://t.co/PDubjbcMe2 https://t.co/rGCSZ3ZT9U
Dr. John Cush @RheumNow( View Tweet )
Mar 02, 2022
Lupus,flare,malar,DermNetNZ

Increased SLE Flares with Hydroxychloroquine Reduction

Mar 01, 2022

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.



While there is literature

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Feb 25, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.




  1. Diagnostic delay in axial spondyloarthritis? Systematic review

Read Article
CARRA Registry looked at TNFi use in JIA and found a nearly 3 fold increased risk of psoriasis. 8225 pts w/ 3.9 yrs of F/U. 54% recv TNFi; the aHR of new onset of psoriasis after TNFi exposure was 2.93 (2.15 to 3.98). MTX had lower risk (HR 0.45) https://t.co/Z6qvlS26M9

Dr. John Cush @RheumNow( View Tweet )

Feb 11, 2022
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Feb 11, 2022

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
×